|
ATE303399T1
(de)
|
2001-03-12 |
2005-09-15 |
Intercept Pharmaceuticals Inc |
Steroide als agonisten für fxr
|
|
WO2011140441A2
(en)
|
2010-05-06 |
2011-11-10 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
PT3336097T
(pt)
|
2012-06-19 |
2020-10-29 |
Intercept Pharmaceuticals Inc |
Preparação da forma não cristalina de ácido obeticólico
|
|
US9982008B2
(en)
|
2012-06-19 |
2018-05-29 |
Intercept Pharmaceuticals, Inc. |
Preparation and uses of obeticholic acid
|
|
SG11201503697TA
(en)
*
|
2012-11-28 |
2015-06-29 |
Intercept Pharmaceuticals Inc |
Treatment of pulmonary disease
|
|
US9814733B2
(en)
*
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
|
WO2014169831A1
(en)
|
2013-04-17 |
2014-10-23 |
Sage Therapeutics, Inc. |
19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
|
|
RU2019126333A
(ru)
|
2013-04-17 |
2019-10-08 |
Сейдж Терапьютикс, Инк. |
19-нор нейроактивные стероиды и способы их применения
|
|
CN113527400B
(zh)
|
2013-04-17 |
2024-06-28 |
萨奇治疗股份有限公司 |
19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
|
|
US20160068563A1
(en)
|
2013-04-17 |
2016-03-10 |
Boyd L. Harrison |
19-nor neuroactive steroids and methods of use thereof
|
|
WO2015010054A2
(en)
|
2013-07-19 |
2015-01-22 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
AU2014308621C1
(en)
|
2013-08-23 |
2022-01-06 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
EP3712254A1
(en)
|
2014-05-28 |
2020-09-23 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into gastric tissues through directed differentiation
|
|
EP3626725B1
(en)
|
2014-05-29 |
2022-11-30 |
Bar Pharmaceuticals S.r.l. |
Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
|
|
WO2015195962A1
(en)
|
2014-06-18 |
2015-12-23 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
WO2016045480A1
(zh)
*
|
2014-09-28 |
2016-03-31 |
上海源力生物技术有限公司 |
一种奥贝胆酸的制备方法
|
|
SMT202000414T1
(it)
|
2014-10-16 |
2020-09-10 |
Sage Therapeutics Inc |
Composizioni e metodi per trattare disturbi del snc
|
|
MX2021004492A
(es)
|
2014-10-16 |
2022-12-05 |
Sage Therapeutics Inc |
Composiciones para el tratamiento de trastornos del snc.
|
|
CA2963704A1
(en)
|
2014-10-17 |
2016-04-21 |
Children's Hospital Medical Center |
In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
|
|
HK1243930A1
(zh)
|
2014-11-06 |
2018-07-27 |
英安塔制药有限公司 |
作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
|
|
EA033445B1
(ru)
|
2014-11-19 |
2019-10-31 |
Nzp Uk Ltd |
5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
|
|
EP3221333B1
(en)
*
|
2014-11-19 |
2019-07-24 |
NZP UK Limited |
6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
|
|
EP3221331B1
(en)
|
2014-11-19 |
2019-09-18 |
Nzp Uk Limited |
6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
|
|
JP6698085B2
(ja)
|
2014-11-19 |
2020-05-27 |
エヌゼットピー ユーケー リミテッド |
ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−６，７−ジオン−ステロイド
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
HK1244708A1
(zh)
|
2014-11-26 |
2018-08-17 |
英安塔制药有限公司 |
作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法
|
|
WO2016086115A1
(en)
|
2014-11-26 |
2016-06-02 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
|
|
ME03749B
(me)
|
2014-11-27 |
2021-04-20 |
Sage Therapeutics Inc |
KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a
|
|
CN105777835B
(zh)
*
|
2014-12-25 |
2020-02-14 |
重庆药友制药有限责任公司 |
一种制备鹅去氧胆酸类似物的方法
|
|
CN105801653B
(zh)
*
|
2014-12-30 |
2018-04-17 |
苏州晶云药物科技有限公司 |
奥贝胆酸的晶型a及其制备方法
|
|
CN105859814A
(zh)
*
|
2015-01-23 |
2016-08-17 |
江苏奥赛康药业股份有限公司 |
一种奥贝胆酸化合物及其药物组合物
|
|
DK3250210T3
(da)
|
2015-01-26 |
2021-03-08 |
Sage Therapeutics Inc |
Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
|
|
TN2017000344A1
(en)
|
2015-02-06 |
2019-01-16 |
Intercept Pharmaceuticals Inc |
Pharmaceutical compositions for combination therapy
|
|
MX2017010376A
(es)
|
2015-02-11 |
2017-12-20 |
Enanta Pharm Inc |
Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
|
|
CN105985395A
(zh)
*
|
2015-02-13 |
2016-10-05 |
江苏奥赛康药业股份有限公司 |
一种奥贝胆酸化合物及含有该化合物的药物组合物
|
|
CN105985396A
(zh)
*
|
2015-02-16 |
2016-10-05 |
苏州泽璟生物制药有限公司 |
氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
|
|
JP6875996B2
(ja)
|
2015-02-20 |
2021-05-26 |
セージ セラピューティクス， インコーポレイテッド |
神経刺激性ステロイド、組成物、およびその使用
|
|
KR20170125927A
(ko)
*
|
2015-03-09 |
2017-11-15 |
인터셉트 파마슈티컬즈, 인크. |
골밀도의 조절 방법
|
|
WO2016161003A1
(en)
|
2015-03-31 |
2016-10-06 |
Enanta Phamraceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
US10894054B2
(en)
|
2015-04-07 |
2021-01-19 |
Intercept Pharmaceuticals, Inc. |
FXR agonist compositions for combination therapy
|
|
CN105777836A
(zh)
*
|
2015-04-09 |
2016-07-20 |
厦门蔚扬药业有限公司 |
奥贝胆酸的多晶型物及其制备方法
|
|
WO2016168553A1
(en)
*
|
2015-04-17 |
2016-10-20 |
Concert Pharmaceuticals, Inc. |
Deuterated obeticholic acid
|
|
PE20180690A1
(es)
*
|
2015-04-27 |
2018-04-23 |
Intercept Pharmaceuticals Inc |
Composiciones de acido obeticolico y metodos de uso
|
|
CN106290594B
(zh)
*
|
2015-05-27 |
2020-07-17 |
中美华世通生物医药科技（武汉）有限公司 |
测定奥贝胆酸片溶出含量的方法
|
|
CN105294801A
(zh)
*
|
2015-07-02 |
2016-02-03 |
扬子江药业集团南京海陵药业有限公司 |
6-乙基鹅去氧胆酸异构体的合成及其分离测定方法
|
|
CZ2015504A3
(cs)
|
2015-07-16 |
2017-01-25 |
Zentiva, K.S. |
Krystalické formy obeticholové kyseliny
|
|
EP3124080A1
(en)
*
|
2015-07-28 |
2017-02-01 |
Merz Pharma GmbH & Co. KGaA |
Semisynthetic bile acids for injection lipolysis
|
|
CN105085597B
(zh)
*
|
2015-08-28 |
2017-03-29 |
成都百裕制药股份有限公司 |
一种无定型奥贝胆酸的制备方法
|
|
CN106478756A
(zh)
*
|
2015-09-02 |
2017-03-08 |
中美华世通生物医药科技（武汉）有限公司 |
Oca-e单晶及其制备方法和用途
|
|
WO2017053428A1
(en)
*
|
2015-09-21 |
2017-03-30 |
Intercept Pharmaceuticals, Inc. |
Methods of promoting hepatic regeneration
|
|
CN108350020A
(zh)
|
2015-09-24 |
2018-07-31 |
英特塞普特医药品公司 |
用于制备胆汁酸衍生物的方法和中间体
|
|
KR20180061351A
(ko)
|
2015-10-07 |
2018-06-07 |
인터셉트 파마슈티컬즈, 인크. |
파네소이드 x 수용체 조절제
|
|
CN106589038A
(zh)
*
|
2015-10-15 |
2017-04-26 |
重庆医药工业研究院有限责任公司 |
一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法
|
|
CN106589039B
(zh)
*
|
2015-10-15 |
2019-12-17 |
苏州朗科生物技术股份有限公司 |
一种奥贝胆酸的制备方法及相关化合物
|
|
CN106632564B
(zh)
*
|
2015-10-30 |
2021-04-13 |
苏州泽璟生物制药股份有限公司 |
奥贝胆酸盐及其无定形物和药物组合物
|
|
CN106668027A
(zh)
*
|
2015-11-05 |
2017-05-17 |
中美华世通生物医药科技（武汉）有限公司 |
奥贝胆酸药物组合物及其制备方法
|
|
KR20180067699A
(ko)
|
2015-11-06 |
2018-06-20 |
인터셉트 파마슈티컬즈, 인크. |
오베티콜산 및 이의 유도체의 제조 방법
|
|
CN106749466B
(zh)
*
|
2015-11-23 |
2019-05-21 |
南京济群医药科技股份有限公司 |
一种高纯度奥贝胆酸的制备方法
|
|
CN105315320B
(zh)
*
|
2015-11-30 |
2017-03-08 |
山东省药学科学院 |
一种制备奥贝胆酸的方法
|
|
CN106810587A
(zh)
*
|
2015-12-01 |
2017-06-09 |
中美华世通生物医药科技（武汉）有限公司 |
制备无定型奥贝胆酸的方法
|
|
CN106810586A
(zh)
*
|
2015-12-01 |
2017-06-09 |
中美华世通生物医药科技（武汉）有限公司 |
奥贝胆酸晶型ⅱ及其制备方法和用途
|
|
CN106822005A
(zh)
*
|
2015-12-03 |
2017-06-13 |
江苏先声药业有限公司 |
奥贝胆酸组合物及其制备方法
|
|
CN106854229A
(zh)
*
|
2015-12-08 |
2017-06-16 |
陈剑 |
一类脂肪酸盐,其制备及其在医药上的应用
|
|
CN105481925B
(zh)
*
|
2015-12-17 |
2018-06-22 |
南京济群医药科技股份有限公司 |
一种奥贝胆酸及其中间体的制备方法
|
|
JP2018538331A
(ja)
*
|
2015-12-22 |
2018-12-27 |
インターセプト ファーマシューティカルズ， インコーポレイテッド |
オベチコール酸の多型結晶形態
|
|
CN105399793A
(zh)
*
|
2015-12-24 |
2016-03-16 |
北京康立生医药技术开发有限公司 |
一种胆烷酸的制备方法
|
|
CN106916195A
(zh)
*
|
2015-12-25 |
2017-07-04 |
中美华世通生物医药科技（武汉）有限公司 |
奥贝胆酸中间体的纯化方法
|
|
WO2017115324A1
(en)
*
|
2016-01-01 |
2017-07-06 |
Lupin Limited |
Solid forms of obeticholic acid and processes thereof
|
|
CN105646633B
(zh)
*
|
2016-01-22 |
2020-05-26 |
南京长澳医药科技有限公司 |
一种制备奥贝胆酸1型的方法
|
|
CN105566429B
(zh)
*
|
2016-01-22 |
2020-12-01 |
南京长澳医药科技有限公司 |
一种奥贝胆酸1型的制备方法
|
|
CN105646634A
(zh)
*
|
2016-01-29 |
2016-06-08 |
中国药科大学 |
奥贝胆酸杂质的制备方法
|
|
JP6842474B2
(ja)
|
2016-02-02 |
2021-03-17 |
深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． |
ステロイド系化合物、当該化合物を含む組成物及びその使用
|
|
EP3411031B1
(en)
*
|
2016-02-04 |
2024-07-24 |
CinDome Pharma, Inc. |
Deuterated domperidone compositions and methods for therapy of disorders
|
|
ES2909907T3
(es)
|
2016-02-10 |
2022-05-10 |
Dr Reddys Laboratories Ltd |
Proceso de purificación que implica la sal de amina del ácido obeticólico
|
|
US10323061B2
(en)
|
2016-02-23 |
2019-06-18 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
|
|
WO2017147137A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
|
|
WO2017147159A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
CN107126419B
(zh)
*
|
2016-02-26 |
2020-06-19 |
石药集团中诺药业（石家庄）有限公司 |
一种奥贝胆酸片剂及其制备方法
|
|
CN109467585A
(zh)
*
|
2016-03-11 |
2019-03-15 |
深圳市塔吉瑞生物医药有限公司 |
用于预防或治疗fxr-介导疾病的胆烷酸化合物
|
|
CN107188917A
(zh)
*
|
2016-03-15 |
2017-09-22 |
正大天晴药业集团股份有限公司 |
奥贝胆酸盐及其药物组合物
|
|
CN105541953B
(zh)
*
|
2016-03-15 |
2017-11-21 |
成都市新功生物科技有限公司 |
一种高纯度奥贝胆酸的重结晶纯化方法
|
|
TW201733582A
(zh)
*
|
2016-03-28 |
2017-10-01 |
大日本住友製藥股份有限公司 |
Fxr促效劑及arb之組合醫藥
|
|
KR20180125573A
(ko)
*
|
2016-03-31 |
2018-11-23 |
인터셉트 파마슈티컬즈, 인크. |
유효 성분의 화학적 안정성이 뛰어난 필름 코팅정
|
|
EP3437646A4
(en)
*
|
2016-03-31 |
2019-11-27 |
Intercept Pharmaceuticals, Inc. |
ORAL PREPARATION WITH EXTRAORDINARY ELABILITY
|
|
US11161871B2
(en)
|
2016-03-31 |
2021-11-02 |
Jiangsu Hengrui Medicine Co., Ltd. |
Crystalline form of obeticholic acid and preparation method therefor
|
|
EP3228306A1
(en)
|
2016-04-04 |
2017-10-11 |
ratiopharm GmbH |
Complex compound comprising obeticholic acid and cyclodextrin and pharmaceutical formulation comprising the complex compound
|
|
CN109311933A
(zh)
|
2016-04-04 |
2019-02-05 |
迪法玛弗朗西斯有限公司 |
制备法尼醇x受体激动剂的方法
|
|
TW201738254A
(zh)
*
|
2016-04-19 |
2017-11-01 |
英特賽普醫藥品公司 |
奧貝膽酸及其衍生物之製備方法
|
|
EP4177335A1
(en)
|
2016-05-05 |
2023-05-10 |
Children's Hospital Medical Center |
Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
|
|
CN105859817A
(zh)
*
|
2016-05-09 |
2016-08-17 |
成都宇西医药技术有限公司 |
一种制备3α-羟基-6-乙烯基-7-酮基-5β-胆烷酸的方法
|
|
GB201608776D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Methods and compounds
|
|
GB201608777D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Compounds
|
|
CN107400154A
(zh)
*
|
2016-05-18 |
2017-11-28 |
北京凯因科技股份有限公司 |
一种制备3α,7α-二-羟基-6α-乙基-5β-胆烷酸的方法
|
|
CN106046094A
(zh)
*
|
2016-05-30 |
2016-10-26 |
福建广生堂药业股份有限公司 |
一种奥贝胆酸二聚体杂质及其制备方法
|
|
CN105859818A
(zh)
*
|
2016-05-31 |
2016-08-17 |
四川瑞希康生物医药有限公司 |
一种奥贝胆酸α晶型及其制备方法、药物组合物和用途
|
|
CN109415405A
(zh)
|
2016-06-01 |
2019-03-01 |
雷迪博士实验室有限公司 |
制备奥贝胆酸的方法
|
|
CN105997909A
(zh)
*
|
2016-06-02 |
2016-10-12 |
中国药科大学 |
一种奥贝胆酸口崩片及其制备方法
|
|
CA3252823A1
(en)
|
2016-06-13 |
2025-02-25 |
Gilead Sciences, Inc. |
Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
|
|
BR112018075734A2
(pt)
|
2016-06-13 |
2019-04-02 |
Gilead Sciences, Inc. |
composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
|
|
CN106083971B
(zh)
*
|
2016-06-17 |
2017-11-14 |
苏州敬业医药化工有限公司 |
一种(E)‑3α‑羟基‑6‑亚乙基‑7‑酮‑5β‑胆烷‑24‑酸的制备方法
|
|
CZ2016385A3
(cs)
|
2016-06-28 |
2018-01-10 |
Zentiva, K.S. |
Způsoby přípravy intermediátů pro syntézu Obeticholové kyseliny
|
|
CN107540720B
(zh)
*
|
2016-06-29 |
2021-03-02 |
常州市第四制药厂有限公司 |
3α,7α-二羟基-6α-乙基-5β-胆烷酸晶型H及其制备方法和应用
|
|
WO2018013613A1
(en)
|
2016-07-11 |
2018-01-18 |
Sage Therapeutics, Inc. |
C17, c20, and c21 substituted neuroactive steroids and their methods of use
|
|
CA3030420C
(en)
|
2016-07-11 |
2025-11-18 |
Sage Therapeutics, Inc. |
C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
|
|
CN107648190B
(zh)
*
|
2016-07-26 |
2021-04-27 |
海南先声药业有限公司 |
奥贝胆酸组合物及其制备方法
|
|
CN106279331B
(zh)
*
|
2016-07-27 |
2019-06-14 |
宋火良 |
胆酸类肝病治疗药物
|
|
CN107674106B
(zh)
*
|
2016-08-01 |
2021-06-22 |
华北制药集团新药研究开发有限责任公司 |
一种奥贝胆酸二聚体的制备方法
|
|
CN106279335A
(zh)
*
|
2016-08-12 |
2017-01-04 |
齐鲁制药有限公司 |
一种制备奥贝胆酸及其中间体的方法
|
|
EP3287467A1
(en)
|
2016-08-22 |
2018-02-28 |
ratiopharm GmbH |
Preparation of obeticholic acid comprising continuous flow process steps
|
|
CN107778339A
(zh)
*
|
2016-08-29 |
2018-03-09 |
鲁南制药集团股份有限公司 |
一种无定型奥贝胆酸的制备方法
|
|
CN115490744A
(zh)
*
|
2016-08-29 |
2022-12-20 |
山东新时代药业有限公司 |
一种3α-羟基-6α-乙基-7-酮-5β-胆-24-酸的制备方法
|
|
EP3293196A1
(en)
|
2016-09-09 |
2018-03-14 |
Hexal AG |
Process for purifying obeticholic acid
|
|
CN106478757B
(zh)
*
|
2016-09-27 |
2019-01-18 |
华南理工大学 |
一种3α,7α-二羟基-6α-乙基胆烷酸的制备方法
|
|
CA3038534A1
(en)
*
|
2016-09-30 |
2018-04-05 |
Intercept Pharmaceuticals, Inc. |
Crystalline forms of a bile acid derivative
|
|
CN107976506B
(zh)
*
|
2016-10-25 |
2020-05-12 |
成都弘达药业有限公司 |
一种奥贝胆酸有关物质的检测方法
|
|
SG11201903697WA
(en)
|
2016-11-04 |
2019-05-30 |
Childrens Hospital Med Ct |
Liver organoid compositions and methods of making and using same
|
|
CN110121347A
(zh)
|
2016-11-29 |
2019-08-13 |
英安塔制药有限公司 |
制备磺酰脲胆汁酸衍生物的方法
|
|
EP3548507A4
(en)
|
2016-12-05 |
2020-07-15 |
Children's Hospital Medical Center |
COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
|
|
US20180243263A1
(en)
*
|
2016-12-09 |
2018-08-30 |
Cadila Healthcare Ltd. |
Treatment for primary biliary cholangitis
|
|
CN108614038B
(zh)
*
|
2016-12-13 |
2022-05-17 |
亚宝药业集团股份有限公司 |
一种测定奥贝胆酸原料药有关物质的方法
|
|
CN106749472B
(zh)
*
|
2016-12-30 |
2019-02-22 |
江苏开元医药化工有限公司 |
一种3α-羟基-6α-乙基-7-酮-5β-胆烷-24-酸的制备方法
|
|
CN106645497A
(zh)
*
|
2017-01-03 |
2017-05-10 |
山东省药学科学院 |
一种奥贝胆酸及其制剂中有关物质的检测方法
|
|
CN110268128A
(zh)
|
2017-01-18 |
2019-09-20 |
特里姆科有限公司 |
结构粘接复合材料
|
|
US10472386B2
(en)
|
2017-02-14 |
2019-11-12 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR agonists and methods of use thereof
|
|
CN106892954B
(zh)
*
|
2017-02-23 |
2019-04-30 |
广州隽沐生物科技有限公司 |
奥贝胆酸的制备工艺
|
|
WO2018165269A2
(en)
*
|
2017-03-08 |
2018-09-13 |
Intercept Pharmaceuticals, Inc |
Crystalline forms of obeticholic acid
|
|
CN110461328A
(zh)
|
2017-03-28 |
2019-11-15 |
吉利德科学公司 |
治疗肝疾病的治疗组合
|
|
CN108659086A
(zh)
*
|
2017-03-29 |
2018-10-16 |
杭州源昶医药科技有限公司 |
一种奥贝胆酸的合成方法
|
|
BR112019020780A2
(pt)
|
2017-04-07 |
2020-04-28 |
Enanta Pharm Inc |
processo para preparação de derivados de ácido biliar de carbamato de sulfonila
|
|
EP3609997A4
(en)
|
2017-04-14 |
2021-03-03 |
Children's Hospital Medical Center |
COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
|
|
CN106986910A
(zh)
*
|
2017-04-19 |
2017-07-28 |
成都百特万合医药科技有限公司 |
奥贝胆酸中间体的制备方法
|
|
EP3613754B1
(en)
|
2017-04-20 |
2023-07-12 |
Daewoong Bio Inc. |
Method for preparing bile acid derivative by using continuous flow reaction
|
|
WO2018211413A1
(en)
*
|
2017-05-15 |
2018-11-22 |
Dr. Reddy’S Laboratories Limited |
Solid forms of obeticholic acid and process for preparation
|
|
CZ2017298A3
(cs)
|
2017-05-26 |
2018-12-05 |
Zentiva, K.S. |
Amorfní formy obeticholové kyseliny
|
|
CN107286160A
(zh)
*
|
2017-06-05 |
2017-10-24 |
毛佳婧 |
一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法
|
|
KR20250109791A
(ko)
*
|
2017-06-23 |
2025-07-17 |
인터셉트 파마슈티컬즈, 인크. |
담즙산 유도체 제조를 위한 방법 및 중간체
|
|
US12478612B2
(en)
|
2017-06-30 |
2025-11-25 |
Cindome Pharma, Inc. |
Deuterated domperidone compositions, methods, and preparation
|
|
KR20240125702A
(ko)
|
2017-06-30 |
2024-08-19 |
신돔 파마, 인크. |
중수소화 돔페리돈 조성물, 방법, 및 제조
|
|
CN109280071A
(zh)
*
|
2017-07-19 |
2019-01-29 |
东莞东阳光药物研发有限公司 |
奥贝胆酸的晶型及其制备方法
|
|
MX2020000873A
(es)
|
2017-07-24 |
2020-07-22 |
Intercept Pharmaceuticals Inc |
Derivados de ácidos biliares marcados isotópicamente.
|
|
KR20200026273A
(ko)
|
2017-08-03 |
2020-03-10 |
(주)메디톡스 |
담즙산류를 제조하기 위한 방법
|
|
CN107383139A
(zh)
*
|
2017-08-09 |
2017-11-24 |
杭州和泽医药科技有限公司 |
一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法
|
|
CN109485687A
(zh)
*
|
2017-09-12 |
2019-03-19 |
成都弘达药业有限公司 |
奥贝胆酸的晶型j及其制备方法
|
|
US12297457B2
(en)
|
2017-10-10 |
2025-05-13 |
Children's Hospital Medical Center |
Esophageal tissue and/or organoid compositions and methods of making same
|
|
US10611793B1
(en)
|
2017-11-27 |
2020-04-07 |
Teva Czech Industries S.R.O. |
Solid state forms of obeticholic acid salts
|
|
WO2019106043A1
(en)
|
2017-11-29 |
2019-06-06 |
Hexal Ag |
Pharmaceutical composition comprising obeticholic acid
|
|
KR20200096596A
(ko)
|
2017-12-08 |
2020-08-12 |
세이지 테라퓨틱스, 인크. |
Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
|
|
EP3727394A4
(en)
|
2017-12-21 |
2021-09-08 |
Children's Hospital Medical Center |
DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
|
|
WO2019145977A1
(en)
*
|
2018-01-25 |
2019-08-01 |
Msn Laboratories Private Limited, R&D Center |
PROCESS FOR THE PREPARATION OF 3α,7α-DIHYDROXY6α-ETHYL-5β-CHOLAN-24-OIC ACID
|
|
CN108440629A
(zh)
*
|
2018-03-16 |
2018-08-24 |
丽珠集团新北江制药股份有限公司 |
一种制备奥贝胆酸中间体及奥贝胆酸的方法
|
|
WO2019197962A1
(en)
*
|
2018-04-09 |
2019-10-17 |
Biophore India Pharmaceuticals Pvt. Ltd |
Crystalline forms of (3α, 5β, 6α, 7α)-6-ethyl-3, 7-dihydroxycholan-24-oic acid (obeticholic acid) and processes thereof
|
|
CN110655550A
(zh)
*
|
2018-06-29 |
2020-01-07 |
江苏海悦康医药科技有限公司 |
(E)-3α-羟基-6-亚乙基-7-氧代-5β-胆甾烷-24-酸的制备方法
|
|
CN108794558B
(zh)
*
|
2018-07-03 |
2020-05-22 |
丽珠集团新北江制药股份有限公司 |
一种反应条件温和的奥贝胆酸制备方法
|
|
US12421500B2
(en)
|
2018-07-26 |
2025-09-23 |
Children's Hospital Medical Center |
Hepato-biliary-pancreatic tissues and methods of making same
|
|
GB201812382D0
(en)
|
2018-07-30 |
2018-09-12 |
Nzp Uk Ltd |
Compounds
|
|
WO2020039449A1
(en)
*
|
2018-08-24 |
2020-02-27 |
Solara Active Pharma Sciences Limited |
An improved process for the preparation of obeticholic acid and intermediates used in the process thereof
|
|
JP2021535753A
(ja)
|
2018-09-12 |
2021-12-23 |
チルドレンズ ホスピタル メディカル センター |
造血幹細胞およびその派生体の生成のためのオルガノイド組成物
|
|
CA3117966A1
(en)
*
|
2018-11-08 |
2020-05-14 |
Intercept Pharmaceuticals, Inc. |
Methods of using obeticholic acid
|
|
CN109535217B
(zh)
*
|
2018-11-13 |
2020-04-14 |
丽珠集团新北江制药股份有限公司 |
一种奥贝胆酸的精制方法
|
|
EP4360632B1
(en)
|
2019-01-15 |
2025-10-29 |
Gilead Sciences, Inc. |
Fxr (nr1h4) modulating compounds
|
|
WO2020160371A1
(en)
|
2019-02-01 |
2020-08-06 |
The University Of Hong Kong |
Innervated organoid compositions and methods of making same
|
|
US11524005B2
(en)
|
2019-02-19 |
2022-12-13 |
Gilead Sciences, Inc. |
Solid forms of FXR agonists
|
|
EA202193334A1
(ru)
|
2019-05-30 |
2022-03-14 |
Интерсепт Фармасьютикалз, Инк. |
Фармацевтические композиции, содержащие агонист fxr и фибрат, для применения при лечении холестатического заболевания печени
|
|
CN114206900A
(zh)
|
2019-05-31 |
2022-03-18 |
萨奇治疗股份有限公司 |
神经活性类固醇及其组合物
|
|
CA3141814A1
(en)
|
2019-05-31 |
2020-12-03 |
Children's Hospital Medical Center |
Shaped organoid compositions and methods of making same
|
|
CN114174494A
(zh)
|
2019-05-31 |
2022-03-11 |
儿童医院医学中心 |
产生和扩增造血干细胞的方法
|
|
WO2021029656A1
(ko)
*
|
2019-08-14 |
2021-02-18 |
주식회사 바이오톡스텍 |
하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
|
|
CN112824425B
(zh)
*
|
2019-11-21 |
2023-10-03 |
成都西岭源药业有限公司 |
一种6-位烯基取代胆酸化合物及其制备方法和应用
|
|
US20230201222A1
(en)
*
|
2020-05-13 |
2023-06-29 |
Children's Hospital Medical Center |
Alleviation of liver injury by activating the signaling pathway mediated by farnesoid x receptor
|
|
WO2022051321A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a fxr agonist
|
|
KR102526452B1
(ko)
*
|
2020-10-28 |
2023-04-27 |
(주)델로 |
관절 구조를 포함하는 토이 로봇
|
|
CN114644670A
(zh)
*
|
2020-12-17 |
2022-06-21 |
四川弘远药业有限公司 |
奥贝胆酸和对氨基苯甲酸的共晶及其制备方法
|
|
CN114236027B
(zh)
*
|
2021-12-22 |
2024-01-12 |
中山百灵生物技术股份有限公司 |
一种(E)-6-亚乙基-3α-羟基-7-酮基-5β-胆甾烷-24-酸的检测方法
|
|
US12343351B2
(en)
|
2022-03-25 |
2025-07-01 |
Rutgers, The State University Of New Jersey |
Pulmonary function treatment
|
|
GB202416085D0
(en)
|
2024-10-31 |
2024-12-18 |
Nzp Uk Ltd |
Reduction process
|